Subscribe
The latest psychology and neuroscience discoveries.
My Account
  • Mental Health
  • Social Psychology
  • Cognitive Science
  • Psychopharmacology
  • Neuroscience
  • About
No Result
View All Result
PsyPost
PsyPost
No Result
View All Result
Home Exclusive Mental Health Parkinson's disease

Psilocybin shows promise for improving mood, cognition, and motor symptoms in Parkinson’s disease

by Eric W. Dolan
May 1, 2025
in Parkinson's disease, Psilocybin
[Adobe Stock]

[Adobe Stock]

Share on TwitterShare on Facebook
Stay informed on the latest psychology and neuroscience research—follow PsyPost on LinkedIn for daily updates and insights.

A small pilot study has found that psilocybin, the active compound in psychedelic mushrooms, may improve not only mood but also cognitive and motor symptoms in individuals with Parkinson’s disease. The results surprised the research team, who initially aimed only to evaluate the drug’s safety. Instead, participants experienced noticeable improvements that lasted for weeks following a single high-dose session. The findings, published in Neuropsychopharmacology, mark the first time a psychedelic has been tested in people with any neurodegenerative disease.

Parkinson’s disease is best known for its motor symptoms, including tremor, stiffness, and slowed movement. But many people with the disease also struggle with depression and anxiety, which often begin years before motor symptoms appear. These mood issues are not just emotionally distressing—they are strongly linked to faster physical decline and worse overall quality of life. Standard treatments for depression and anxiety, such as antidepressants, are often less effective in people with Parkinson’s, making the search for new therapeutic options especially urgent.

Psilocybin is a naturally occurring psychedelic compound that is converted in the body into psilocin, which interacts with serotonin receptors in the brain. Studies in major depression and anxiety linked to terminal illness have shown that even a single dose of psilocybin, when paired with psychotherapy, can lead to rapid and long-lasting improvements in mood. Scientists believe the drug may help the brain form new neural connections, a property referred to as neuroplasticity. These effects may be particularly relevant for people with Parkinson’s disease, who exhibit disrupted serotonin signaling, inflammation, and loss of neural connectivity—all factors that may contribute to both mood and motor symptoms.

Given the complex neurobiology of Parkinson’s and concerns about possible drug interactions and psychosis risk, the research team at the University of California, San Francisco set out to test the safety and tolerability of psilocybin in this population. They enrolled 12 participants between the ages of 40 and 75, all of whom had mild to moderate Parkinson’s disease and met diagnostic criteria for depression or anxiety. People with significant cognitive impairment, active psychosis, or other medical risks were excluded from the trial. Most participants were already being treated with levodopa, the most common medication for managing motor symptoms of Parkinson’s.

Each participant underwent two supervised psilocybin sessions on a research unit at UCSF. The first dose was a lower, safety-focused 10 milligram dose, followed about two weeks later by a higher, 25 milligram therapeutic dose. Both sessions were paired with multiple psychotherapy visits before and after. The therapists provided preparation, emotional support during the experience, and integration afterward.

To track the effects of psilocybin, the researchers used a range of assessments. These included standard clinical rating scales for motor and non-motor Parkinson’s symptoms, mood and anxiety measures, cognitive performance tasks, and caregiver observations. Safety was monitored throughout the sessions, including blood pressure, heart rate, and reports of any adverse psychological or physical effects.

The study found that psilocybin was generally well tolerated. The most common side effects during the sessions included mild anxiety, nausea, and temporary increases in heart rate or blood pressure. Two participants reported intense anxiety during one of the sessions, and one of them experienced a transient worsening of tremor and increased thoughts about death related to future disability. However, no serious adverse events occurred, and suicidal ideation decreased overall after treatment.

Beyond safety, the researchers observed a range of improvements across different symptom domains. Participants reported significant reductions in depression and anxiety one week after the high-dose session, and these gains were maintained at the three-month follow-up. Motor symptoms also improved, as measured by both self-reports and clinician ratings. These included reductions in everyday motor difficulties and improvements in motor exam scores. The magnitude of these improvements exceeded thresholds considered clinically meaningful.

Cognitive function also improved in several domains. Participants performed better on tests of memory, spatial working memory, and cognitive flexibility. These gains were still present a month after the psilocybin session. Interestingly, caregiver reports also reflected meaningful changes. Family members noted that participants were less distressed by neuropsychiatric symptoms and showed fewer behavioral issues. They also expressed high satisfaction with the treatment.

While the improvements in mood were expected based on prior research in depression, the benefits in motor symptoms and cognition were unexpected. The authors suggest several possible explanations. One is that psilocybin may directly influence dopamine and serotonin signaling in ways that support motor control. Another is that improving mood may indirectly benefit motor function, as depression is associated with increased stress and biological changes that can worsen physical symptoms. A third possibility is that psilocybin may influence the underlying disease process through its effects on inflammation, neural plasticity, or other brain systems disrupted in Parkinson’s.

“We are still in very early stages of this work, but this first study went well beyond what we expected,” said the paper’s first author, Ellen Bradley, an assistant professor and associate director of UCSF’s Translational Psychedelic Research Program (TrPR). “Many people don’t realize this, but mood symptoms in Parkinson’s are linked to a faster physical decline. And they are actually a stronger predictor of patients’ quality of life with Parkinson’s than their motor symptoms.”

But the study has important limitations. With only 12 participants and no placebo group, the findings must be interpreted with caution. Expectancy effects and the powerful psychological context of the therapy sessions may have contributed to the observed improvements. Also, because the study excluded people with more advanced disease or significant medical complications, it’s unclear how generalizable the results are. Future research will need to include more diverse and larger samples to better understand the risks and benefits.

Encouraged by the results of this pilot study, the researchers have launched a larger randomized controlled trial involving 100 participants across two sites: UCSF and Yale University. This follow-up study will include brain imaging, noninvasive brain stimulation, and blood tests to help identify how psilocybin affects the brain and immune system. The hope is to uncover biological mechanisms behind the clinical improvements and determine whether psilocybin could one day become part of Parkinson’s care.

“The vast majority of brain diseases still lack interventions that change the course of illness,” said the study’s senior author, Joshua Woolley, an associate professor at UCSF and director of the TrPR Program. “We can often treat the symptoms, but we don’t alter the trajectory or prevent decline. Now, that’s beginning to change. These results raise the exciting possibility that psilocybin may help the brain repair itself.”

The study, “Psilocybin therapy for mood dysfunction in Parkinson’s disease: an open-label pilot trial,” was authored by Ellen R. Bradley, Kimberly Sakai, Gisele Fernandes-Osterhold, Balázs Szigeti, Connie Ludwig, Jill L. Ostrem, Caroline M. Tanner, Meredith A. Bock, Katiah Llerena, Patrick R. Finley, Aoife O’Donovan, Jose Rafael P. Zuzuarregui, Zachary Busby, Amber McKernan, Andrew D. Penn, Aliss C. C. Wang, Raymond C. Rosen, and Joshua D. Woolley.

TweetSendScanShareSendPin1ShareShareShareShareShare

RELATED

Scientists uncover kidney-to-brain route for Parkinson’s-related protein spread
Neuroimaging

Scientists uncover kidney-to-brain route for Parkinson’s-related protein spread

June 22, 2025

A groundbreaking study suggests that Parkinson’s disease may begin in the kidneys, where a toxic protein builds up and travels to the brain. This discovery could reshape our understanding of the disease’s origins and risk factors.

Read moreDetails
Some dark personality traits may help buffer against depression, new psychology research suggests
Mental Health

Psilocybin-assisted therapy linked to reduced depression in people with bipolar disorder, small study finds

June 17, 2025

A pilot study involving psilocybin-assisted therapy found possible antidepressant effects for people with bipolar II disorder. The treatment appeared well-tolerated, with no signs of mania or psychosis, offering cautious optimism for future bipolar depression research.

Read moreDetails
Psilocybin from “magic” mushrooms weakens the brain’s response to angry faces
Addiction

Single-dose psilocybin therapy shows promise for reducing alcohol consumption

June 15, 2025

Early results from a pilot study indicate that psilocybin-assisted therapy could be linked to lower alcohol consumption and improved psychological outcomes, though larger controlled trials are needed to determine whether the psilocybin itself is responsible for these changes.

Read moreDetails
Psilocybin appears to have a uniquely powerful relationship with nature relatedness
Neuroimaging

Psilocybin induces large-scale brain network reorganization, offering insights into the psychedelic state

June 14, 2025

A new study using high-resolution EEG reveals that psilocybin dramatically alters brain connectivity in rats. The psychedelic induced dose-dependent changes in network organization, disrupting normal patterns of neural communication and suggesting rodents may be viable models for studying altered consciousness.

Read moreDetails
Meta-analysis highlights potential of psilocybin therapy for treatment-resistant depression
Depression

Psilocybin therapy shows similar benefits for patients with and without recent antidepressant use

June 11, 2025

A new study finds that individuals with treatment-resistant depression experienced similar improvements from psilocybin-assisted psychotherapy whether or not they had recently discontinued antidepressant medications.

Read moreDetails
Single-dose psilocybin therapy shows promise for veterans with treatment-resistant depression
Psilocybin

21-year-old man dies after jabbing pencil into his brain during psilocybin trip

June 5, 2025

A detailed case report describes how a 21-year-old man died from self-inflicted ocular trauma during a bad psilocybin trip. The tragic event illustrates how rare but extreme reactions to psychedelics can lead to fatal outcomes.

Read moreDetails
Clinical psychologists appear to have cautiously favorable attitudes toward psychedelic-assisted mental health treatments
Psilocybin

Only a specific dose of psilocybin induces lasting antidepressant-like effects, study suggests

May 27, 2025

A recent study found that a single moderate dose of psilocybin produced lasting antidepressant-like effects in rats, while higher doses led to unwanted side effects. The findings highlight the importance of optimal dosing.

Read moreDetails
Psilocybin and escitalopram produce antidepressant effects via distinct brain mechanisms, study suggests
Depression

Psilocybin and escitalopram produce antidepressant effects via distinct brain mechanisms, study suggests

May 25, 2025

A new study using brain scans found that psilocybin and escitalopram reduce depression symptoms through different neural mechanisms. While escitalopram dampened emotional brain activity, psilocybin preserved or slightly increased it, suggesting distinct pathways to recovery.

Read moreDetails

SUBSCRIBE

Go Ad-Free! Click here to subscribe to PsyPost and support independent science journalism!

STAY CONNECTED

LATEST

Romantic breakups follow a two-stage decline that begins years before the split, study finds

Believing “news will find me” is linked to sharing fake news, study finds

A common parasite not only invades the brain — it can also decapitate human sperm

Almost all unmarried pregant women say that the fetus resembles the father, study finds

New neuroscience research reveals brain antioxidant deficit in depression

Scientists uncover kidney-to-brain route for Parkinson’s-related protein spread

Scientists reveal a surprising link between depression and microbes in your mouth

New study sheds light on the psychological roots of collective violence

         
       
  • Contact us
  • Privacy policy
  • Terms and Conditions
[Do not sell my information]

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

Subscribe
  • My Account
  • Cognitive Science Research
  • Mental Health Research
  • Social Psychology Research
  • Drug Research
  • Relationship Research
  • About PsyPost
  • Contact
  • Privacy Policy